Detailed description of the recommended starting dose and adjustment principles of Trametinib (Megenin)

Trametinib is an oral MEK1/MEK2 inhibitor, mainly used to treat BRAF V600E or V600K Melanoma patients with mutations can also be used for certain BRAF mutation-driven non-small cell lung cancer (NSCLC). It inhibits the MAPK signaling pathway to prevent tumor cell proliferation and survival, thereby achieving anti-tumor effects. Correct dosage selection is critical for efficacy and safety.

The standard starting dose for adult patients is oral administration 2 mg Once daily, preferably at a fixed time to maintain stable blood concentration. The tablets should be swallowed whole and should not be chewed or crushed. They can be taken with or on an empty stomach and are not affected by food. The starting dose is suitable for the vast majority of patients who have not received MEK inhibitor treatment, which can achieve better efficacy and facilitate observation of tolerance.

During the treatment, if **≥3 grade adverse reactions** (such as rash, edema, diarrhea, cardiac dysfunction or eye toxicity), the medication should be suspended until the symptoms improve to ≤1 grade, and then gradually returned to the original dose or reduced to 1.5 based on tolerance. mg/day or 1 mg/day. Mild to moderate adverse reactions can be managed through symptomatic treatment or extended dosing intervals without immediate dose reduction. Children or patients with impaired liver and kidney function need to adjust the dosage under the guidance of a doctor.

During the entire treatment process, heart function, blood pressure, fundus and skin conditions should be monitored regularly to detect adverse reactions and adjust the dose in a timely manner. If the patient tolerates it well but has poor efficacy, maintenance of the standard dose or combination with other targeted drug treatments under the guidance of a professional physician may be considered. Overall, the dose management of trametinib should follow the principle of "starting from a standard starting dose, adjusting according to tolerance, and regularly monitoring and follow-up" to balance efficacy and safety.

Reference materials:https://www.drugs.com/